Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis.

[1]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[2]  Claudio J. Verzilli,et al.  Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration , 2011, European heart journal.

[3]  J. Flack,et al.  A Common KIF6 Polymorphism Increases Vulnerability to Low-Density Lipoprotein Cholesterol: Two Meta-Analyses and a Meta-Regression Analysis , 2011, PloS one.

[4]  V. Fuster,et al.  Can we dramatically reduce the incidence of coronary heart disease? , 2011, Nature Reviews Cardiology.

[5]  W. Rathmann,et al.  Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque , 2011, Nature Genetics.

[6]  Christian Gieger,et al.  Genetic Variants in Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk , 2011, Nature.

[7]  Simon C. Potter,et al.  Large-Scale Gene-Centric Analysis Identifies Novel Variants for Coronary Artery Disease , 2011, PLoS genetics.

[8]  Gonçalo R. Abecasis,et al.  Fine Mapping of Five Loci Associated with Low-Density Lipoprotein Cholesterol Detects Variants That Double the Explained Heritability , 2011, PLoS genetics.

[9]  N. Mehta.  Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. , 2011, Circulation. Cardiovascular genetics.

[10]  C. Carlson,et al.  Genetic Determinants of Lipid Traits in Diverse Populations from the Population Architecture using Genomics and Epidemiology (PAGE) Study , 2011, PLoS genetics.

[11]  Mark I. McCarthy,et al.  A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease , 2011, Nature Genetics.

[12]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[13]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[14]  Inês Barroso,et al.  Genetic Variants Influencing Circulating Lipid Levels and Risk of Coronary Artery Disease , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[15]  L. Peltonen,et al.  A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses , 2010, The Lancet.

[16]  Daniel Steinberg,et al.  Earlier intervention in the management of hypercholesterolemia: what are we waiting for? , 2010, Journal of the American College of Cardiology.

[17]  B. Horne,et al.  Joint effects of common genetic variants from multiple genes and pathways on the risk of premature coronary artery disease. , 2010, American heart journal.

[18]  Simon C. Potter,et al.  Genetic Determinants of Major Blood Lipids in Pakistanis Compared With Europeans , 2010, Circulation. Cardiovascular genetics.

[19]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[20]  Børge G Nordestgaard,et al.  PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. , 2010, Journal of the American College of Cardiology.

[21]  Marcia M. Nizzari,et al.  Candidate Gene Association Resource (CARe): Design, Methods, and Proof of Concept , 2010, Circulation. Cardiovascular genetics.

[22]  Nancy R Cook,et al.  Association between a literature-based genetic risk score and cardiovascular events in women. , 2010, JAMA.

[23]  G. Moneta,et al.  Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[24]  Tom R. Gaunt,et al.  Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. , 2009, American journal of human genetics.

[25]  P. Ridker,et al.  Forty-Three Loci Associated with Plasma Lipoprotein Size, Concentration, and Cholesterol Content in Genome-Wide Analysis , 2009, PLoS genetics.

[26]  Shahrul Mt-Isa,et al.  Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. , 2009, JAMA.

[27]  Alberto Piazza,et al.  Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants , 2009, Nature Genetics.

[28]  P. Deloukas,et al.  Large Scale Association Analysis of Novel Genetic Loci for Coronary Artery Disease , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[29]  R. Collins,et al.  Common variants at 30 loci contribute to polygenic dyslipidemia , 2009, Nature Genetics.

[30]  Christian Gieger,et al.  Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts , 2009, Nature Genetics.

[31]  J. Ordovás,et al.  Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. , 2008, Atherosclerosis.

[32]  C. Gieger,et al.  Lifelong Reduction of LDL-Cholesterol Related to a Common Variant in the LDL-Receptor Gene Decreases the Risk of Coronary Artery Disease—A Mendelian Randomisation Study , 2008, PloS one.

[33]  R. Płoski,et al.  Effect of protein convertase subtilisin/kexin type 9 (PCSK9) 46L gene polymorphism on LDL cholesterol concentration in a Polish adult population. , 2008, Molecular genetics and metabolism.

[34]  S. Kathiresan.  A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. , 2008, The New England journal of medicine.

[35]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.

[36]  D. Strachan,et al.  LDL-cholesterol concentrations: a genome-wide association study , 2008, The Lancet.

[37]  R. Collins,et al.  Newly identified loci that influence lipid concentrations and risk of coronary artery disease , 2008, Nature Genetics.

[38]  Dolores Corella,et al.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.

[39]  J. Goldstein,et al.  Lowering LDL--Not Only How Low, But How Long? , 2006, Science.

[40]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[41]  L. Smeeth,et al.  Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. , 2006, American journal of epidemiology.

[42]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[43]  Richard M. Moe,et al.  Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. , 2004, Journal of the American College of Cardiology.

[44]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[45]  C McRae,et al.  Myocardial infarction. , 2019, Australian family physician.

[46]  F. Sebening,et al.  [Coronary artery disease]. , 1980, Verhandlungen der Deutschen Gesellschaft fur Herz- und Kreislaufforschung.